Drug
Vy1706 Low Dose
Vy1706 Low Dose: highest development phase Phase 1, developed by Voyager Therapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Voyager Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| VY1706 Low dose NCT07764146 | Phase 1 | Alzheimer s Disease |
Latest
No recent events.
Follow Vy1706 Low Dose on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.